Compare REE & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REE | PMN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 23.5M |
| IPO Year | N/A | N/A |
| Metric | REE | PMN |
|---|---|---|
| Price | $0.67 | $11.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.75 | ★ $72.67 |
| AVG Volume (30 Days) | ★ 132.2K | 17.9K |
| Earning Date | 03-16-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $207,000.00 | N/A |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $6.27 |
| 52 Week High | $9.53 | $39.75 |
| Indicator | REE | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 74.00 |
| Support Level | $0.69 | $8.96 |
| Resistance Level | $0.78 | $10.18 |
| Average True Range (ATR) | 0.07 | 0.65 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 21.31 | 85.03 |
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.